- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Analyst Retains ‘Buy’ Take on WeedMD Following Hiku Reversal
A new report from Greg McLeish with Mackie Research Capital issued a “Buy” rating for WeedMD and increased his one-year price target to C$4.
A new analyst report values the potential for a medically focussed cannabis producer after suffering a reversal in a potential merger.
Greg McLeish, analyst with Mackie Research Capital covering the cannabis space issued a new research data report stamping WeedMD (TSX:WMD) with a one-year price target of C$4 and retained his “Buy” rating.
McLeish highlighted the company’s current cash situation and said its funded capacity provides a strong asset.
“This strong cash position will also allow management to pursue strategic acquisitions and address potential working capital requirements,” McLeish wrote, according to Cantech Letter.
WeedMD was stuck in a business turnabout from Hiku Brands (CSE:HIKU), a company with which it held an arrangement to essentially merge both businesses.
As the deal continued to move forward, Canopy Growth (TSX:WEED; NYSE:CGC) entered the picture with an acquisition offer for Hiku.
“Ultimately, together we [Canopy and Hiku] will continue to build one of the world’s most engaging and successful cannabis retail and brand business,” Alan Gertner, CEO of Hiku said in a statement.
Thanks to the annulment from Hiku, WeedMD obtained a C$10 million termination fee, which the company highlighted as part of its cash position.
WeedMD’s stock declined immediately following the announcement from Canopy and Hiku, and continued with the company reaching a C$1.49 price point per share from its previous close on Tuesday (July 17).
Since the Hiku reversal on July 10, WMD has declined in price 27.32 percent.
McLeish’s new projection comes after endorsing the original merger with Hiku in a previous note.
Investor takeaway
Support from the financial community for WeedMD shows a strong foundation from the cannabis producer as it recovers and begins searching a potential new entry into the recreational cannabis space.
WeedMD will now have to deliver on its business strategy for investors to return to its side following the decline of the Hiku reversal.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Hiku Brands is a client of the Investing News Network. This article is not paid-for content.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.